Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “buy” rating restated by equities researchers at Roth Capital in a research report issued on Tuesday.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.97% on Tuesday, hitting $331.86. The stock had a trading volume of 1,209,762 shares. Regeneron Pharmaceuticals has a one year low of $227.64 and a one year high of $352.49. The stock’s 50-day moving average is $303. and its 200-day moving average is $305.5. The company has a market cap of $32.757 billion and a P/E ratio of 93.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, August 5th. The company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the previous year, the company posted $1.73 earnings per share. The company’s revenue for the quarter was up 45.4% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $9.90 earnings per share for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday. They now have a $425.00 price target on the stock, up previously from $410.00. Separately, analysts at Argus initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $375.00 price target on the stock. Finally, analysts at Morgan Stanley reiterated a “positive” rating on shares of Regeneron Pharmaceuticals in a research note on Thursday, July 10th. They now have a $310.00 price target on the stock. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $343.89.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.